| NCT06947304 | Evaluation of Miricorilant on Liver Fat in Patients With MASLD | RECRUITING | PHASE1 | 2025-08-01 | 2026-03 | 2026-03 |
| NCT06906341 | Relacorilant in Combination With Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer | RECRUITING | PHASE2 | 2025-04-11 | 2026-12 | 2026-08 |
| NCT06928779 | Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant | COMPLETED | PHASE1 | 2024-10-08 | 2024-12-09 | 2024-12-09 |
| NCT06495944 | Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Participants | COMPLETED | PHASE1 | 2024-05-31 | 2024-08-02 | 2024-08-02 |
| NCT06108219 | A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH) | ACTIVE_NOT_RECRUITING | PHASE2 | 2023-10-25 | 2026-09 | 2026-09 |
| NCT05772169 | Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST) | COMPLETED | PHASE4 | 2023-03-31 | 2024-12-18 | 2024-11-19 |
| NCT05712265 | Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant | COMPLETED | PHASE1 | 2023-01-24 | 2023-02-23 | 2023-02-23 |
| NCT05407324 | Dazucorilant in Patients With Amyotrophic Lateral Sclerosis | ACTIVE_NOT_RECRUITING | PHASE2 | 2022-11-15 | 2027-05 | 2024-10-22 |
| NCT05257408 | Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer | ACTIVE_NOT_RECRUITING | PHASE3 | 2022-06-29 | 2026-03 | 2025-03-24 |
| NCT05347979 | Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants | COMPLETED | PHASE1 | 2022-05-25 | 2022-07-19 | 2022-07-19 |
| NCT05553470 | Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant | COMPLETED | PHASE1 | 2022-03-03 | 2024-09-13 | 2024-09-13 |
| NCT05117489 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH) | COMPLETED | PHASE1 | 2021-11-23 | 2024-01-29 | 2024-01-29 |
| NCT04990310 | Single Dose Absorption, Distribution, Metabolism, and Excretion Study of [14C]-CORT113176 in Healthy Male Participants | COMPLETED | PHASE1 | 2021-08-18 | 2021-09-20 | 2021-09-20 |
| NCT05003713 | Single and Multiple Ascending Dose Study of CORT125236 in Healthy Participants | COMPLETED | PHASE1 | 2021-08-03 | 2023-02-03 | 2023-02-03 |
| NCT04994743 | Safety, Tolerability, and Pharmacokinetic Study of CORT113176 in Healthy Participants | COMPLETED | PHASE1 | 2021-07-13 | 2021-09-30 | 2021-09-30 |
| NCT04795479 | T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers | COMPLETED | PHASE1 | 2021-01-22 | 2021-07-13 | 2021-05-17 |
| NCT03823703 | Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH) | TERMINATED | PHASE2 | 2020-11-04 | 2021-04-05 | 2021-04-05 |
| NCT04672512 | Single and Multiple Ascending Dose Study of CORT125329 in Healthy Participants | COMPLETED | PHASE1 | 2020-10-23 | 2022-01-17 | 2022-01-17 |
| NCT04373265 | Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol) | COMPLETED | PHASE1 | 2020-09-30 | 2024-01-12 | 2023-10-17 |
| NCT06094738 | A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects | COMPLETED | PHASE1 | 2020-09-19 | 2020-11-16 | 2020-11-16 |
| NCT04524403 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II) | COMPLETED | PHASE2 | 2020-09-09 | 2022-08-25 | 2022-07-29 |
| NCT04308590 | A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas | COMPLETED | PHASE3 | 2020-07-27 | 2024-09-19 | 2024-09-19 |
| NCT04329949 | Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | TERMINATED | PHASE3 | 2020-06-30 | 2022-03-25 | 2021-08-23 |
| NCT04672499 | Single and Multiple Dose Study of Miricorilant (CORT118335) Tablet Formulations in Healthy Participants | COMPLETED | PHASE1 | 2020-04-27 | 2020-09-07 | 2020-09-07 |
| NCT04249323 | Single and Multiple Ascending Dose Study of CORT113176 in Healthy Participants | COMPLETED | PHASE1 | 2020-01-27 | 2020-10-15 | 2020-10-15 |
| NCT06094725 | A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant | COMPLETED | PHASE1 | 2020-01-06 | 2020-12-14 | 2020-12-14 |
| NCT03818256 | A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications | COMPLETED | PHASE2 | 2019-12-04 | 2022-07-06 | 2022-06-17 |
| NCT03776812 | Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | COMPLETED | PHASE2 | 2019-04-05 | 2023-07-12 | 2021-03-16 |
| NCT03877562 | The Effect of CORT118335 on Olanzapine-Induced Weight Gain | COMPLETED | PHASE1 | 2019-04-01 | 2020-03-25 | 2020-03-13 |
| NCT03697109 | A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome | COMPLETED | PHASE3 | 2018-11-15 | 2024-04-15 | 2024-04-08 |
| NCT03877952 | Mass Balance Recovery and Metabolite Profile of CORT125281 in Healthy Male Participants | COMPLETED | PHASE1 | 2018-09-13 | 2018-11-02 | 2018-11-01 |
| NCT03878264 | Absolute Bioavailability and Metabolism Study of CORT118335 in Healthy Male Participants | COMPLETED | PHASE1 | 2018-08-06 | 2019-03-24 | 2019-03-24 |
| NCT03540836 | A Study to Determine the Relative Bioavailability of Two New Relacorilant Capsule Variants | COMPLETED | PHASE1 | 2018-05-24 | 2018-07-25 | 2018-07-16 |
| NCT03604198 | Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome | ACTIVE_NOT_RECRUITING | PHASE2 | 2018-05-07 | 2025-12 | 2025-12 |
| NCT03512548 | Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its Metabolites | COMPLETED | PHASE1 | 2018-04-10 | 2019-08-23 | 2019-07-29 |
| NCT03457597 | Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s | COMPLETED | PHASE1 | 2018-03-06 | 2018-04-28 | 2018-04-15 |
| NCT03442621 | Relacorilant Food Effect Study in Healthy Subjects | COMPLETED | PHASE1 | 2018-01-16 | 2018-03-09 | 2018-02-28 |
| NCT03437941 | Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC | COMPLETED | PHASE1, PHASE2 | 2017-12-15 | 2023-01-09 | 2023-01-09 |
| NCT03335956 | CORT125281 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) | COMPLETED | PHASE1 | 2017-09-21 | 2018-06-25 | 2018-05-31 |
| NCT03315338 | First-in-human Study in Healthy Subjects | COMPLETED | PHASE1 | 2017-09-15 | 2019-02-22 | 2019-02-22 |
| NCT03258372 | Crossover Drug-Drug Interaction Study to Determine Effects of Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites | COMPLETED | PHASE1 | 2017-08-16 | 2017-11-29 | 2017-11-29 |
| NCT03259542 | Mifepristone Drug-Drug Interaction Study With CYP3A Inhibitor | COMPLETED | PHASE1 | 2017-08-09 | 2017-12-11 | 2017-12-11 |
| NCT06094790 | A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy Subjects | COMPLETED | PHASE1 | 2017-05-18 | 2017-11-15 | 2017-11-15 |
| NCT03067376 | A Study Designed to See How [14C]-CORT125134 is Taken up, Broken Down and Removed From the Body | COMPLETED | PHASE1 | 2016-08 | 2016-09 | 2016-09 |
| NCT02804750 | Study to Evaluate CORT125134 in Participants With Cushing's Syndrome | COMPLETED | PHASE2 | 2016-06 | 2018-09 | 2018-09 |
| NCT02762981 | Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors | COMPLETED | PHASE1, PHASE2 | 2016-05-23 | 2020-09-12 | 2020-05-12 |
| NCT06094712 | A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male Subjects | COMPLETED | PHASE1 | 2016-04-07 | 2016-04-27 | 2016-04-27 |
| NCT03508635 | CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) | COMPLETED | PHASE1 | 2014-09 | 2015-12 | 2015-12 |
| NCT02014337 | Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors | COMPLETED | PHASE1 | 2014-01 | 2017-12 | 2017-12 |
| NCT01925092 | Mifepristone in Children With Refractory Cushing's Disease | WITHDRAWN | PHASE3 | 2013-08 | | 2016-12 |
| NCT01371565 | Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome | COMPLETED | PHASE3 | 2010-11 | 2012-09 | 2012-06 |
| NCT00936741 | An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome | COMPLETED | PHASE3 | 2009-07 | 2012-09 | 2012-09 |
| NCT00698022 | A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers | COMPLETED | PHASE1 | 2008-11 | 2009-02 | 2009-02 |
| NCT00752843 | A Phase I Study to Determine the Effect of Mifepristone on the Pharmacokinetics of Fluvastatin in Healthy Volunteers | COMPLETED | PHASE1 | 2008-09 | 2008-11 | 2008-11 |
| NCT00637494 | A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features | TERMINATED | PHASE3 | 2008-03 | 2014-06 | 2014-06 |
| NCT00569582 | A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome | COMPLETED | PHASE3 | 2007-12 | | 2011-01 |
| NCT00455442 | A Two-Week Study of the Efficacy and Safety of Mifepristone in the Prevention of Olanzapine-Induced Weight Gain | COMPLETED | PHASE2 | 2007-03 | 2007-07 | |
| NCT00128505 | An International Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression | COMPLETED | PHASE3 | 2005-08 | 2006-11 | 2006-11 |
| NCT00208156 | A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression | COMPLETED | PHASE3 | 2005-05 | 2006-11 | 2006-11 |
| NCT00146523 | An International Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression | COMPLETED | PHASE3 | 2005-05 | 2006-07 | 2006-07 |
| NCT00130676 | A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression | COMPLETED | PHASE3 | 2004-09 | 2006-06 | 2006-06 |
| NCT00128479 | A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression | COMPLETED | PHASE3 | 2004-09 | 2007-01 | 2007-01 |